Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | PDE8B | O95263 | 1/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31663797 | 0.97 | ALOX5AP (0.47) | ALOX5APFEN1CHEK2F2RL3GPR119 | |
| SCHEMBL29619024 | 0.89 | ALOX5AP (0.43) | ALOX5APFEN1CHEK2PDE8BF2RL3 | |
| SCHEMBL31663816 | 0.86 | ALOX5AP (0.41) | ALOX5APFEN1CHEK2F2RL3GPR119 | |
| SCHEMBL31663763 | 0.85 | NPC1 (0.44) | ALOX5APFEN1F2RL3 | |
| SCHEMBL31663765 | 0.85 | NPC1 (0.44) | ALOX5APFEN1F2RL3 | |
| SCHEMBL31663788 | 0.85 | NPC1 (0.44) | ALOX5APFEN1F2RL3 | |
| SCHEMBL31663755 | 0.83 | ALOX5AP (0.43) | ALOX5APFEN1F2RL3GPR119 | |
| SCHEMBL31663807 | 0.83 | NPC1 (0.44) | ALOX5APFEN1F2RL3 | |
| SCHEMBL31663796 | 0.82 | JAK2 (0.41) | ALOX5APFEN1F2RL3 | |
| SCHEMBL31663811 | 0.82 | FPR3 (0.39) | ALOX5APFEN1CHEK2F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4236937-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2025-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | HTR2A, HTR5A, HTR1A | ALOX5AP 100/4885FEN1 2279/4885CHEK2 1426/4885 |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR2C, HTR1A, HTR2A | ALOX5AP 606/4885FEN1 3355/4885CHEK2 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.